like
genebas
vaccin
enter
human
vaccin
area
soon
veterinari
vaccin
employ
concept
alreadi
licens
multitud
clinic
trial
infecti
diseas
differ
form
cancer
ongo
highli
import
develop
novel
vaccin
safeti
aspect
also
new
adjuv
deliveri
techniqu
need
care
investig
meet
shortand
longterm
safeti
requir
one
novel
vivo
deliveri
method
plasmid
vaccin
electropor
applic
short
puls
electr
current
immedi
site
inject
genet
vaccin
method
shown
significantli
augment
transfect
efficaci
subsequ
vaccinespecif
immun
respons
howev
dramat
increas
deliveri
efficaci
offer
electropor
rais
concern
potenti
increas
risk
integr
plasmid
dna
host
genom
demonstr
safeti
lack
integr
immun
high
dose
multigen
vaccin
deliv
intraderm
use
needl
free
devic
biojector
togeth
electropor
use
derma
vax
tm
dna
vaccin
skin
deliveri
system
demonstr
plasmid
persist
skin
site
inject
least
four
month
immun
howev
associ
plasmid
dna
genom
dna
could
detect
analyz
qpcr
follow
field
invers
gel
electrophoresi
separ
heavi
light
dna
fraction
shortli
initi
phase
clinic
trial
healthi
volunt
immun
multiplasmid
vaccin
use
combin
deliveri
method
jetinject
intraderm
electropor
clinic
investig
plasmid
dna
primarili
focus
two
vivo
applic
gene
therapi
immun
order
verifi
safeti
efficaci
two
applic
requir
differ
approach
plasmid
immun
aim
rapidli
induc
immun
respons
safeti
reason
plasmid
prefer
clear
rapidli
bodytissu
contrast
gene
therapi
applic
aim
introduc
genet
materi
target
tissu
without
evok
immun
respons
could
serv
elimin
cell
express
therapeut
agent
effort
prove
safeti
plasmid
dna
biodistribut
plasmid
studi
sever
anim
speci
result
publish
experi
indic
plasmid
rapidli
clear
bodi
tabl
directli
inject
skin
muscl
low
level
plasmid
transport
via
blood
stream
therefor
often
detect
variou
organ
earli
time
point
see
front
matter
elsevi
ltd
right
reserv
tabl
previou
experi
analyz
plasmid
persist
immun
doserout
speciessex
max
local
conc
site
inject
liver
spleen
gonad
hiv
gagpol
winegar
et
al
g
im
rabbit
cg
h
cg
h
cg
h
cg
h
malaria
pfcsp
parker
et
al
g
im
mous
cg
h
cg
h
cg
cg
h
cg
cg
h
cg
hiv
gag
manam
et
al
g
im
nd
cg
cg
w
cg
cg
w
cg
cg
w
hiv
gagenvpolvifneftatvpu
kim
et
tabl
howev
plasmid
eventu
often
rapidli
clear
organ
normal
found
exclus
site
inject
later
time
point
safeti
reason
presenc
plasmid
gonad
given
special
attent
studi
plasmid
detect
testi
ovari
one
week
immun
tabl
moreov
indic
either
insert
gene
plasmid
backbon
play
major
role
distribut
persist
plasmid
introduct
vivo
electropor
increas
uptak
immunogen
plasmid
vaccin
reenerg
field
genet
immun
current
sever
electropor
devic
evalu
clinic
trial
cancer
infecti
diseas
http
termelectropor
howev
sinc
electropor
dramat
increas
transfect
efficaci
concern
rais
method
might
affect
persist
plasmid
dna
target
tissu
may
result
increas
risk
integr
foreign
dna
host
chromosom
dna
report
singl
public
present
studi
multigen
vaccin
hiv
deliv
intraderm
needl
free
jetinject
follow
electropor
vaccin
previous
evalu
without
addit
electropor
sever
clinic
trial
shown
safe
immunogen
toxicolog
biodistribut
persist
potenti
integr
plasmid
hiv
vaccin
analyz
vaccin
includ
seven
plasmid
fig
vector
follow
gene
envelop
gene
env
env
b
env
c
b
c
respect
rev
pkcmvrev
rt
revers
transcriptas
pkcmvrtmut
gag
gag
b
b
respect
previous
describ
encod
subtyp
b
fusion
protein
gp
encod
chimer
protein
hypervari
loop
exchang
subtyp
c
sequenc
respect
encod
hiv
subtyp
b
subtyp
b
gene
exchang
gene
subtyp
regulatori
protein
rev
nativ
enzym
rt
mutat
enzymeact
site
protein
deriv
hiv
subtyp
b
good
manufactur
practic
gmp
grade
dna
vaccin
produc
vecura
karolinska
hospit
sweden
experi
describ
immun
procedur
describ
seven
plasmid
deliv
two
entiti
one
contain
gag
ba
b
rt
gene
contain
env
b
c
rev
gene
order
avoid
interfer
antigen
mice
sedat
isofluran
shave
lower
back
immun
intraderm
shave
area
two
separ
jet
inject
use
biojector
bioject
medic
technolog
inc
usa
syring
intraderm
spacer
anim
inject
g
dna
vaccin
entiti
concentr
mg
dnaml
salin
immedi
follow
inject
site
inject
subject
electropor
use
derma
vax
tm
commerci
dna
vaccin
deliveri
system
cyto
puls
scienc
inc
md
usa
needl
array
cyto
puls
scienc
inc
needl
per
row
use
electropor
puls
protocol
use
two
puls
vcm
durat
plu
eight
puls
vcm
ms
durat
control
anim
inject
l
salin
immun
procedur
ten
male
femal
balbc
mice
immun
plasmid
vaccin
male
femal
inject
salin
anim
immun
four
occas
week
describ
anim
regularli
weigh
observ
chang
behaviour
fur
qualiti
two
week
last
vaccin
administr
anim
anaesthetis
blood
obtain
orbit
plexu
analysi
regard
white
red
blood
cell
count
wbc
rbc
respect
haemoglobin
hgb
platelet
count
plt
hematocrit
hct
sera
analyz
regard
aspart
transaminas
ast
alanin
transaminas
alt
bilirubin
albumin
creatinin
lactas
dehydrogenas
ldh
gammaglutamyltransferas
ggt
potassium
sodium
glucos
histopatholog
investig
follow
organ
analys
brain
lung
ileum
liver
heart
spleen
kidney
test
ovari
mesenter
lymph
node
inguin
lymph
node
noninject
skin
skin
inject
site
biodistribut
experi
femal
balbc
mice
immun
variou
timepoint
follow
immun
one
anim
sacrif
cervic
disloc
anim
care
dissect
use
separ
set
tool
individu
organ
order
avoid
contamin
organ
snapfrozen
collect
use
still
frozen
organ
slice
scalpel
extract
total
dna
perform
frozen
sampl
use
dnaeasi
blood
tissu
kit
qiagen
hilden
germani
accord
manufactur
instruct
quantit
polymeras
chain
reaction
qpcr
perform
use
taqmanbas
assay
organ
anim
use
abi
prism
ht
fast
realtim
pcr
system
appli
biosystem
primer
probe
use
qpcr
reaction
design
react
plasmid
pkcmv
backbon
thu
analys
independ
insert
gene
level
detect
determin
copi
plasmidg
total
dna
limit
quantif
determin
copi
plasmidg
dna
establish
level
inhibit
tissu
type
copi
plasmid
ad
extract
dna
tissu
type
prior
pcr
reaction
sampl
contain
inhibitori
factor
dilut
water
extent
pcr
reaction
longer
inhibit
follow
pcr
sampl
contain
extract
dna
tissu
type
shown
inhibit
pcr
reaction
dilut
appropri
level
femal
balbc
mice
purchas
charl
river
breed
facil
germani
studi
includ
immun
mice
untreat
control
mice
anim
hous
per
cage
clean
room
plasmid
vaccin
handl
prior
studi
anim
inject
g
dna
accord
procedur
describ
day
inject
anim
kill
cervic
disloc
shave
thoroughli
use
dispos
singleus
razor
skin
lower
part
back
remov
anim
use
scissor
forcep
one
set
instrument
use
mous
avoid
contamin
anim
sampl
snapfrozen
liquid
nitrogen
kept
analysi
associ
plasmid
dna
high
molecular
weight
dna
analysi
perform
althea
technolog
inc
ca
usa
dna
subsequ
extract
skin
site
inject
immun
salin
inject
mice
amount
dna
determin
uv
spectrophotometri
dna
mice
pool
salin
control
immun
mice
respect
order
obtain
enough
dna
subsequ
gelsepar
heavi
light
dna
dna
analys
use
qpcr
paramet
describ
biodistribut
analysi
plasmid
content
copiesg
dna
materi
subject
eagi
restrict
digest
subsequ
field
invers
gel
electrophoresi
fige
h
invers
ratio
upon
complet
fige
high
molecular
weight
dna
excis
gel
analys
qpcr
case
detect
level
plasmid
remain
hmw
fraction
first
round
separ
fige
subsequ
qpcr
repeat
lymphocyt
deriv
spleen
refer
splenocyt
isol
male
femal
anim
toxicolog
experi
ficollpaqu
plu
amersham
bioscienc
europ
uppsala
sweden
use
purifi
splenocyt
subsequ
suspend
rpmi
medium
sigmaaldrich
stockholm
sweden
supplement
penicillinstreptomycin
pest
invitrogen
corpor
carlsbad
ca
fetal
calf
serum
sigmaaldrich
stockholm
sweden
cell
distribut
antiifnantibodypreco
polyvinyliden
fluoridebottom
plate
mabtech
ab
nacka
sweden
stimul
splenocyt
peptid
thermo
fisher
scientif
waltham
overlap
amino
acid
cover
protein
subtyp
b
use
final
concentr
g
peptideml
control
peptid
librari
consist
peptid
deriv
tickborn
enceph
viru
medium
alon
use
control
concanavalin
g
per
well
use
posit
control
confirm
cell
viabil
plate
develop
instruct
manufactur
mabtech
ab
nacka
sweden
result
given
cytokineproduc
spotform
cell
sfc
per
splenocyt
respond
anim
defin
sfc
per
plate
cell
twice
number
sfc
unstimul
cell
anim
femal
male
mice
immun
intraderm
use
biojector
salin
plasmid
vaccin
occas
week
salin
plasmid
g
total
dna
inject
volum
l
immedi
thereaft
inject
site
electropor
derma
vax
tm
dna
vaccin
deliveri
system
gener
health
statu
chang
food
intak
activ
fur
qualiti
immun
anim
deviat
salineinject
control
anim
throughout
studi
bodi
weight
anim
record
timesweek
end
studi
signific
differ
bodi
weight
found
group
femal
howev
male
mice
vaccin
group
statist
signific
higher
bodi
weight
male
control
anim
mean
differ
g
obviou
reason
differ
weight
gain
group
could
identifi
clinic
chemistri
paramet
significantli
differ
group
femal
mice
male
statist
signific
differ
group
found
level
lactas
dehydrogenas
ldh
sodium
ldh
valu
unknown
reason
unusu
high
control
group
among
male
femal
suggest
observ
relat
treatment
differ
sodium
level
group
small
consid
biolog
signific
clinic
chemistri
paramet
analyz
significantli
differ
group
male
histopatholog
chang
found
follow
tissu
could
suspect
result
treatment
brain
lung
ileum
liver
heart
spleen
kidney
test
ovari
mesenter
lymph
node
inguin
lymph
node
noninject
skin
sampl
skin
inject
site
sign
tissu
reaction
occasion
found
reflect
heal
inflammatori
respons
previou
inject
procedur
reaction
includ
increas
number
inflammatori
cell
dermi
subcuti
remnant
small
epiderm
crust
contain
keratin
dead
cell
sometim
disrupt
epidermi
conclud
repeat
inject
plasmid
hiv
vaccin
follow
electropor
well
toler
anim
studi
perform
accord
good
laboratori
practic
glp
visionar
preclin
ab
uppsala
sweden
order
investig
biodistribut
plasmid
follow
immun
femal
balbc
mice
inject
g
total
dna
plasmid
mixtur
accord
procedur
describ
control
anim
inject
l
salin
procedur
anim
immun
hous
visionar
preclin
ab
uppsala
accord
glp
major
organ
collect
dna
extract
subject
quantit
pcr
qpcr
analysi
use
primer
probe
design
detect
plasmid
pkcmv
backbon
sensit
copi
plasmidg
total
extract
dna
except
skin
inject
site
underli
muscl
vaccin
plasmid
readili
clear
major
organ
tabl
day
detect
plasmid
spleen
analyz
anim
day
post
immun
could
detect
low
level
plasmid
lung
analyz
anim
tabl
day
post
immun
plasmid
dna
vaccin
clear
organ
except
skin
inject
site
tabl
fig
level
plasmid
inject
site
decreas
substanti
time
end
exper
tabl
biodistribut
pkcmv
quantit
pcr
result
copi
pkcmv
per
microgram
total
dna
plasmidsg
dna
day
day
day
day
tabl
iment
day
post
immun
sever
thousand
copi
plasmidg
extract
dna
still
remain
order
investig
potenti
risk
integr
plasmid
dna
host
genom
perform
studi
design
quantifi
amount
plasmid
dna
associ
high
molecular
weight
dna
genom
dna
site
inject
day
immun
plasmid
vaccin
mice
immun
dna
salin
describ
materi
al
method
section
fige
use
separ
high
molecular
weight
genom
dna
extrachromosom
plasmid
dna
follow
separ
qpcr
assay
use
detect
potenti
genom
integr
plasmid
vector
primer
use
qpcr
analysi
use
biodistribut
assay
design
detect
plasmid
backbon
independ
insert
vaccin
gene
number
copi
pkcmv
plasmid
detect
genom
dna
vaccinetr
skin
rang
per
g
dna
prior
gel
separ
tabl
follow
restrict
enzym
digest
gel
electrophoresi
primari
fige
number
copi
pkcmv
detect
pool
rang
copi
per
microgram
hmw
dna
hmw
dna
isol
gel
subject
second
round
fige
secondari
fige
sampl
test
assay
limit
quantif
indic
minim
risk
plasmid
dna
integr
host
genom
dna
readout
success
genetransf
express
result
subsequ
vaccinespecif
immun
respons
measur
cellular
immun
respons
set
anim
toxicolog
studi
assess
blood
chemistri
paramet
spleen
collect
femal
male
anim
group
splenocyt
isol
analyz
vaccinespecif
immun
respons
fig
vaccinespecif
immun
respons
analys
elispot
mabtech
ab
nacka
sweden
splenocyt
stimul
overlap
peptid
cover
either
subtyp
b
immun
mice
femal
male
respond
antigen
env
gag
strongest
immun
respons
could
detect
femal
mice
direct
gag
fig
plasmid
vaccin
develop
evalu
clinic
trial
prevent
treatment
mani
differ
infecti
diseas
cancer
plasmid
vaccin
shown
excel
safeti
profil
ten
year
pass
sinc
first
clinic
trial
includ
genet
vaccin
conclud
howev
plasmid
vaccin
far
induc
moder
immun
respons
man
best
respons
obtain
boost
recombin
microbi
vector
recombin
protein
howev
applic
vivo
electropor
increas
transfect
efficaci
immunogen
plasmid
vaccin
anim
model
sever
fold
current
sever
clinic
trial
ongo
order
determin
benefit
methodolog
translat
success
use
human
howev
signific
increas
transfect
efficaci
observ
electropor
rais
concern
prolong
persist
plasmid
target
tissu
increas
risk
integr
plasmid
dna
host
genom
although
electropor
unlik
influenc
distribut
plasmid
organ
reason
assum
effici
transfect
could
affect
local
persist
plasmid
site
inject
shown
present
studi
plasmid
dna
inde
rapidli
clear
organ
except
site
inject
underli
muscl
day
low
amount
plasmid
could
found
spleen
lung
respect
howev
day
plasmid
could
detect
analyz
organ
besid
skin
site
inject
presenc
plasmid
spleen
day
could
potenti
result
immun
cell
obtain
plasmid
site
inject
follow
traffick
spleen
reason
low
detect
level
plasmid
observ
lung
day
unclear
possibl
explan
detect
plasmid
lung
might
mice
inhal
plasmid
groom
high
level
plasmid
skin
day
plasmid
temporarili
get
retain
fine
mesh
capillari
surround
alveoli
lung
analys
show
plasmid
retain
site
inject
day
perform
extens
integr
studi
skin
inject
site
qpcr
use
quantifi
plasmid
extract
dna
allow
detect
low
plasmid
copiesg
total
dna
correspond
sensit
diploid
cell
result
integr
experi
confirm
persist
plasmid
inject
site
skin
day
show
associ
plasmid
dna
host
chromosom
dna
tabl
previou
studi
shown
transfect
antigenexpress
cell
concentr
deepest
layer
skin
also
found
hypodermi
well
dermi
epidermi
unknown
compart
major
plasmid
retain
one
assum
intraand
extracellular
local
involv
risk
integr
electropor
report
singl
studi
level
integr
demonstr
studi
low
would
worst
case
scenario
result
level
integr
similar
rate
spontan
geneinactiv
mutat
contrast
result
report
indic
increas
immun
respons
induc
electropor
result
effici
clear
plasmidantigen
consequ
potent
cytotox
respons
kill
transfect
antigenexpress
cell
moreov
experi
conduct
aim
incorpor
genet
materi
host
chromosom
inde
confirm
plasmid
vector
highli
ineffici
purpos
viral
vector
much
power
purpos
integr
gene
therapi
studi
thu
serv
addit
safeti
data
plasmid
dna
vaccin
applic
emphas
difficulti
achiev
integr
use
plasmid
dna
inject
result
toxicolog
evalu
show
vaccin
deliv
jet
inject
electropor
well
toler
nontox
mice
safeti
vaccin
strengthen
fact
amount
dna
use
mice
g
correspond
roughli
mg
plasmid
dnakg
bodi
weight
substanti
higher
g
plasmid
dnakg
bodi
weight
plan
clinic
test
vaccin
strategi
furthermor
skin
deliveri
contrast
intramuscular
deliveri
allow
possibl
visual
inspect
inject
site
thu
make
easier
detect
potenti
malign
chang
conclus
high
dose
highli
immunogen
vaccin
plasmid
deliv
intraderm
jet
inject
follow
electropor
shown
safe
result
integr
plasmid
dna
host
genom
vaccin
deliveri
method
present
recent
approv
swedish
medic
product
agenc
shortli
enter
phase
clinic
trial
stockholm
involv
healthi
nonhiv
infect
volunt
